Autoimmune Bullous Diseases Associated With Immune Checkpoint Inhibitors: An Analysis Based on a Systematic Review
International Journal of Dermatology · 2026-07 · 65 (7) · 1420-1430
DOI: 10.1111/ijd.70362 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Dermatology, online erschienen am 06.03.2026. Verfasst von Min Zou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Skin Diseases, Vesiculobullous, Autoimmune Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben.
Abstract (Originalsprache)
Background
Autoimmune bullous diseases (AIBDs) constitute a rare yet potentially life‐threatening subset of immune‐related adverse events induced by immune checkpoint inhibitors (ICIs). However, the characteristics of ICI‐induced AIBDs (ICI‐AIBDs) and the factors influencing patient survival remain incompletely characterized. Therefore, we aimed to synthesize the available information on ICI‐AIBD patients and sought to explore factors potentially influencing the survival outcome of this population.
Methods
A systematic search of 5 databases was conducted. Cox regression analysis was used to identify potential factors affecting patient survival outcomes.
Results
Finally, a total of 188 studies with 319 participants were analyzed. The spectrum of AIBDs comprised bullous pemphigoid ( n = 254, 79.6%), lichen planus pemphigoides ( n = 34, 10.7%), mucous membrane pemphigoid ( n = 11, 3.4%), pemphigus group ( n = 7, 2.2%), linear IgA bullous dermatosis ( n = 5, 1.6%), primarily induced by programmed cell death protein 1 inhibitors. In the exploratory analysis, female (hazard ratio [HR], 2.35; 95% confidence interval [CI], 1.10–5.02; p = 0.020) and pemphigus group (HR, 7.09; 95% CI, 1.87–26.96; p = 0.003) were potentially associated with higher mortality, whereas topical glucocorticoid therapy was potentially protective (HR, 0.44; 95% CI, 0.21–0.93; p = 0.025).
Conclusions
In conclusion, we delineate the full clinical spectrum of ICI‐AIBDs, tentatively exploring factors potentially affecting patients' survival, which provides insights for individualized therapy and may inform future clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venereology, West China Hospital, Sichuan University, Chengdu, China.
- Department of Dermatology & Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China.
- The First School of Clinical Medicine, Southern Medical University, Guangzhou, China.
ORCID-Profile: Min Zou, Xun Feng, Jishu Li, Yue Xiao, Wei Yan, Wei Li
Zitieren
APA
Zou, M., Feng, X., Zhan, K., Wang, H., Pang, J., Li, J., Peng, G., Wei, M., Li, L., Xiao, Y., Yan, W., & Li, W. (2026). Autoimmune Bullous Diseases Associated With Immune Checkpoint Inhibitors: An Analysis Based on a Systematic Review. International Journal of Dermatology, 65(7), 1420-1430. https://doi.org/10.1111/ijd.70362
Vancouver
Zou M, Feng X, Zhan K, Wang H, Pang J, Li J, et al. Autoimmune Bullous Diseases Associated With Immune Checkpoint Inhibitors: An Analysis Based on a Systematic Review. International Journal of Dermatology. 2026;65(7):1420-1430. doi:10.1111/ijd.70362
BibTeX
@article{Zou2026,
author = {Zou, Min and Feng, Xun and Zhan, Kun and Wang, Hongli and Pang, Jiyun and Li, Jishu and Peng, Guo and Wei, Mintong and Li, Luyuan and Xiao, Yue and Yan, Wei and Li, Wei},
title = {Autoimmune Bullous Diseases Associated With Immune Checkpoint Inhibitors: An Analysis Based on a Systematic Review},
journal = {International Journal of Dermatology},
year = {2026},
volume = {65},
number = {7},
pages = {1420--1430},
doi = {10.1111/ijd.70362}
}
EUVIMED